Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators designed to help investors select stocks with the highest potential to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Value Score focuses on identifying undervalued stocks using financial ratios like P/E, PEG, and Price/Sales to find attractive investment opportunities [3] - The Growth Score assesses a company's financial health and future outlook by analyzing projected and historical earnings, sales, and cash flow to identify stocks with sustainable growth potential [4] - The Momentum Score identifies optimal times to invest based on price trends and earnings estimate changes, emphasizing the importance of following market trends [5] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investment strategies [6] Zacks Rank and Style Scores Integration - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to assist investors in building successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [7][8] - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 that also have Style Scores of A or B, while stocks with a 3 (Hold) rank should also possess high Style Scores to ensure potential upside [9][10] Company Spotlight: Universal Health Services (UHS) - Universal Health Services Inc. operates various healthcare facilities and currently holds a 3 (Hold) rating on the Zacks Rank, with a VGM Score of A and a Momentum Style Score of B, indicating potential for growth [11] - Recent analyst revisions have positively impacted UHS's earnings estimates for fiscal 2025, with the Zacks Consensus Estimate rising by $0.19 to $19.43 per share, alongside an average earnings surprise of 13.8% [12]

exceptional, high-quality one-on-one personalized care they have come to expect from Hope Cancer Care of Nevada." "We're excited to welcome patients to our new Henderson location, where we will provide the same high- quality care that we do in all of our clinics," said Dr. Mehdi. "We have a patient-first mindset, and we hold ourselves to a high-standard of continuously providing exceptional, compassionate care, which is the standard in all of Hope Cancer Care of Nevada's clinic locations. We look forward to ...

CERRITOS, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that effective July 1, it will be the exclusive oncology provider for over 80,000 Medicaid patients associated with SilverSummit Healthplan in Nevada. TOI is known for bringing state-of-the-art cancer care to the communities it serves, and their presence in the Las Vegas market will provide enhanced access to care and hig ...

Group 1 - OSE Immunotherapeutics has published its inaugural Letter to Shareholders, highlighting key achievements, growth strategy foundations, and future perspectives [1] - The company is focused on developing first-in-class assets in immuno-oncology and immuno-inflammation to meet unmet patient needs [2] - OSE Immunotherapeutics collaborates with leading academic institutions and biopharmaceutical companies to develop transformative medicines for serious diseases [2] Group 2 - The company is headquartered between Nantes and Paris and is listed on Euronext [2] - Additional information about the company's assets can be found on its website [3]

This presentation and the accompanying oral presentation, if any, contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of Health Catalyst, Inc. and its subsidiaries ("Health Catalyst" or the "Company"), market size and growth opportunities, competitive p ...

Company Overview - QIAGEN N.V. has announced a partnership with GENCURIX, Inc. to develop oncology assays for the QIAcuityDx digital PCR platform, marking the first development partner under QIAGEN's QIAcuityDx Partnering Program [1][9] - The collaboration is expected to significantly enhance QIAGEN's Precision Diagnostics business within the Diagnostic Solutions product group [2] Market Position and Financials - QIAGEN has a market capitalization of $10.35 billion and an earnings yield of 5%, which is significantly higher than the industry's -29.3% yield [4] - Over the past year, QIAGEN shares have increased by 8.1%, contrasting with a 16.1% decline in the industry [12] Strategic Initiatives - The QIAcuityDx Partnering Program aims to support third-party assay development, with over 2,700 cumulative placements of the QIAcuityDx platform expected by the end of 2024 [5] - GENCURIX will leverage its expertise in multiplex IVD assay development to create oncology tests, with QIAGEN responsible for marketing these assays globally upon regulatory approval [6][9] Industry Insights - The global IVD market was valued at $108.30 billion in 2024 and is projected to grow at a compound annual growth rate of 5.6% through 2030, driven by demand for accurate and rapid diagnostic solutions [10]

NovoCure (NVCR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individual ...

Group 1 - Champions Oncology (NASDAQ: CSBR) is a specialized platform providing preclinical research services focused on oncology [1] - The company is at a critical inflection point, evolving its business model by monetizing its unique data asset through licensing [1] Group 2 - The investment thesis suggests that identifying high-quality and/or severely mispriced investment ideas is essential for potential investors [1]

Core Viewpoint - Gilead Sciences, Inc. (GILD) is initiated with a Strong Buy rating and a price target of $181, focusing on its transformative therapies in HIV, viral hepatitis, oncology, and other unmet medical needs globally [1]. Group 1: Company Overview - Gilead is engaged in the discovery, development, and commercialization of therapies that address significant medical needs [1]. - The company operates in various therapeutic areas, including HIV, viral hepatitis, and oncology, indicating a diversified portfolio [1]. Group 2: Research Methodology - Moretus Research employs a structured, repeatable framework to identify companies with durable business models and mispriced cash flow potential [1]. - The research emphasizes rigorous fundamental analysis combined with a judgment-driven process, focusing on clarity and actionable insights [1]. - Valuation methods are based on sector-relevant multiples tailored to each company's business model, ensuring comparability and relevance [1]. Group 3: Investment Philosophy - Moretus Research targets underappreciated companies undergoing structural changes or temporary dislocations, where disciplined analysis can yield asymmetric returns [1]. - The research aims to elevate the standard for independent investment research by providing professional-grade insights and a strong filter for essential information in equity analysis [1].

Key Takeaways Four GARP stocks, FLEX, CVS, URBN, and EXEL, were selected using a screen focused on PEG and value scores. Each pick has a PEG ratio below industry median, solid earnings outlook and a Zacks Rank of #1 or #2. FLEX leads with a 35.1% historical growth rate, while EXEL boasts 21.2% expected long-term earnings growth.In the equity market, investments always need to be prudently hedged to overcome uncertainties and limit losses related to external shocks. A question that often arises is whether ...